publicações selecionadas
-
artigo académico
- Glucocorticoid receptor-dependent therapeutic efficacy of tauroursodeoxycholic acid in preclinical models of Spinocerebellar ataxia type 3. Journal of Clinical Investigation. 2024
- Mitochondrial Dysfunction and Decreased Cytochrome c in Cell and Animal Models of Machado-Joseph Disease. Cells. 2023
- Cell-based therapeutic strategies for treatment of spinocerebellar ataxias: an update. Neural Regeneration Research. 2023
- Assessment of the gastrointestinal fate of bacterial nanocellulose and its toxicological effects after repeated-dose oral administration. Environmental Science-Nano. 2023
- Cerebellar neuronal dysfunction accompanies early motor symptoms in spinocerebellar ataxia type 3. Disease Models & Mechanisms. 2022
- MorphData: Automating the data extraction process of morphological features of microglial cells in ImageJ. Journal of Open Research Software. 2022
- IP 3 R2 null mice display a normal acquisition of somatic and neurological development milestones. European Journal of Neuroscience. 2021
- Polyglutamine spinocerebellar ataxias: emerging therapeutic targets. Expert Opinion on Therapeutic Targets. 2020
- Regulation of neuronal mRNA splicing and Tau isoform ratio by ATXN3 through deubiquitylation of splicing factors. The EMBO Journal. 2020
-
artigo de conferência
-
artigo de revista
- Intrathecal Injection of the Secretome from ALS Motor Neurons Regulated for miR-124 Expression Prevents Disease Outcomes in SOD1-G93A Mice. Biomedicines. 2022
- Microglial Depletion Has No Impact on Disease Progression in a Mouse Model of Machado-Joseph Disease. Cells. 2022
- Profiling Microglia in a Mouse Model of Machado-Joseph Disease. Biomedicines. 2022
- Preclinical Evidence Supporting Early Initiation of Citalopram Treatment in Machado-Joseph Disease. Molecular Neurobiology. 2019
- Citalopram Reduces Aggregation of ATXN3 in a YAC Transgenic Mouse Model of Machado-Joseph Disease. Molecular Neurobiology. 2018
- Neuroprotective Effects of Creatine in the CMVMJD135 Mouse Model of Spinocerebellar Ataxia Type 3. Movement Disorders. 2018
-
documento
- The skeletal muscle in SCA3: contribution to disease, potential for biomarker development and therapeutic target 2023
- Serotonergic signaling modulation as a therapeutic approach for spinocerebellar ataxia type 3: unveiling the molecular pathways 2023
- Limited Therapeutic Impact of Intermittent Fasting and Ketogenic diets in a Mouse Model of Spinocerebellar Ataxia Type 3 2023
- The glucocorticoid receptor as a biomarker and neuronal therapeutic target of a disease-improving bile acid in SCA3/MJD 2023
- Unraveling the ATXN3 interactome: clues on its contribution for physiology and disease 2023
- Assessing the HPA-axis mediated stress responses in a mouse model of SCA3 2023
- The Glucocorticoid Receptor as a Biomarker and Neuronal Therapeutic Target of a Disease-Improving Bile Acid in SCA3/MJD 2022
- Motor coordination and balance ameliorated after treatment of the CMVMJD135 mouse model of Spinocerebellar Ataxia Type 3 with befiradol 2022
- The study of depression and cognitive comorbidities in a mouse model of spinocerebellar ataxia type 3 2022
- The molecular tweezer CLR01 reduces motor impairments and neuropathology in spinocerebellar ataxia type 3 in vivo models 2022
- A new lead compound for triple negative breast cancer therapy 2021
- A new therapeutic option for triple negative breast cancer 2021
- Unravelling the anticancer potential of novel compounds for breast cancer therapy 2020
- New chromene derivatives: unravelling the molecular mechanisms for breast cancer treatment 2019
- Serotonergic signaling activation suppresses proteotoxicity 2019
- Exploitation of novel chromene derivatives for breast cancer treatment 2019
- Exploitation of novel chromene derivatives for breast cancer treatment. 2019
- New chromene derivatives: Unraveling the molecular mechanisms for breast cancer therapy 2019
- New chromene derivatives: Unraveling the molecular mechanisms for breast cancer therapy. 2019
- In vitro and in vivo evaluation of new chromene derivatives as potent anticancer agents 2019
- In vitro and in vivo evaluation of new chromene derivatives as potent anticancer agents. 2019